Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...